Efficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adults

Expert Review of Vaccines

Volumn 10, Issue 8, 2011, Pages 1127-1130

  Ambrose, Christopher S ^a  

^a MEDIMMUNE   (United States)

Author keywords

antibody; correlate of protection; efficacy; inactivated vaccine; influenza

Indexed keywords

HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE;

ADULT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; INFLUENZA; NORMAL HUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION;

EID: 80052064980     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.101     Document Type: Article

References (16)

1. Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 377(9767), 751-759 (2011)
2. Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J. Infect. Dis. 200(12), 1861-1869 (2009)
3. Frey S, Vesikari T, Szymczakiewicz- Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin. Infect. Dis. 51(9), 997-1004 (2010)
4. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N. Engl. J. Med. 361(13), 1260-1267 (2009)
5. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 355(24), 2513-2522 (2006) (Pubitemid 44917499)
6. Jackson L, Gaglani M, Keyserling H, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect. Dis. 10(1), 71 (2010)
7. Beran J, Wertzova V, Honegr K, et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect. Dis. 9, 2 (2009)
8. Ohmit SE, Victor JC, Teich ER, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J. Infect. Dis. 198, 312-317 (2008)
9. Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC. Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad. Med. J. 49(569), 159-163 (1973)
10. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J. Infect. Dis. 203(9), 1309-1315 (2011)
11. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 28(Suppl. 4), D45-D53 (2010)
12. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med. Res. Methodol. 10, 18 (2010)
13. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10(5), 780-786 (2003) (Pubitemid 37129487)
14. Nauta JJ, Beyer WE, Osterhaus AD. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals 37(4), 216-221 (2009)
15. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J. Infect. Dis. 196(9), 1304-1312 (2007) (Pubitemid 351412002)
16. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev. Biol. 115, 63-73 (2003)